Fas ligand expression in lynch syndrome-associated colorectal tumours

Pathology and Oncology Research

Volumn 15, Issue 3, 2009, Pages 399-406

  Koornstra, Jan J ^a   De Jong, Steven ^a   Boersma Van Eck, Wietske ^a   Zwart, Nynke ^a   Hollema, Harry ^a   De Vries, Elisabeth G E ^a   Kleibeuker, Jan H ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Apoptosis; Colorectal cancer; Counterattack; Fas ligand; HNPCC; Lynch syndrome

Indexed keywords

FAS LIGAND;

ADULT; AGED; ARTICLE; COLORECTAL ADENOMA; COLORECTAL CANCER; COLORECTAL CARCINOMA; CONTROLLED STUDY; CORRELATION ANALYSIS; FAMILIAL CANCER; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION; TUMOR ASSOCIATED LEUKOCYTE;

ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; FAS LIGAND PROTEIN; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MIDDLE AGED; TUMOR MARKERS, BIOLOGICAL;

EID: 73449104581     PISSN: 12194956     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12253-008-9136-7     Document Type: Article

References (54)

1. YM Hendriks AE de Jong H Morreau, et al. 2006 Diagnostic approach and management of Lynch syndrome (hereditary nonpolyposis colorectal carcinoma): a guide for clinicians CA Cancer J Clin 56 213 225 10.3322/canjclin.56.4.213 16870997 (Pubitemid 44175050)
2. CR Boland SN Thibodeau SR Hamilton, et al. 1998 A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer Cancer Res 58 5248 5257 1:CAS:528:DyaK1cXnsFSmtbk%3D 9823339
3. WH De Vos tot Nederveen Cappel FM Nagengast G Griffioen, et al. 2002 Surveillance for hereditary nonpolyposis colorectal cancer: a long-term study on 114 families Dis Colon Rectum 45 1588 1894 10.1007/s10350-004-7244-3 12473880 (Pubitemid 35471007)
4. HF Vasen FM Nagengast PM Khan 1995 Interval cancers in hereditary nonpolyposis colorectal cancer (Lynch syndrome) Lancet 345 1183 1184 10.1016/S0140-6736(95)91016-6 1:STN:280:DyaK2M3ktVegtg%3D%3D 7723574
5. M Ponz de Leon CG Della P Benatti, et al. 1998 Frequency and type of colorectal tumors in asymptomatic high-risk individuals in families with hereditary nonpolyposis colorectal cancer Cancer Epidemiol Biomarkers Prev 7 639 641 1:STN:280:DyaK1czksVylsg%3D%3D 9681535
6. FE Rijcken H Hollema JH Kleibeuker 2002 Proximal adenomas in hereditary non-polyposis colorectal cancer are prone to rapid malignant transformation Gut 50 382 386 10.1136/gut.50.3.382 1:STN:280:DC%2BD387ivF2iug%3D%3D 11839719 (Pubitemid 34161056)
7. JJ Koornstra S de Jong H Hollema, et al. 2003 Changes in apoptosis during the development of colorectal cancer: a systematic review of the literature Crit Rev Oncol Hematol 45 37 53 10.1016/S1040-8428(01)00228-1 1:STN:280:DC%2BD38jitVGmsQ%3D%3D 12482571 (Pubitemid 35449787)
8. SM Woerner M Kloor M von Knebel Doeberitz, et al. 2006 Microsatellite instability in the development of DNA mismatch repair deficient tumors Cancer Biomark 2 69 86 1:CAS:528:DC%2BD28XovFWlt74%3D 17192061
9. P Möller K Koretz F Leithäuser, et al. 1994 Expression of APO-1 (CD95), a member of the NGF/TNF receptor superfamily, in normal and neoplastic colon epithelium Int J Cancer 57 371 377 10.1002/ijc.2910570314 8168998 (Pubitemid 24168612)
10. C Belluco G Esposito R Bertorelle, et al. 2002 Fas ligand is up-regulated during the colorectal adenoma-carcinoma sequence Eur J Surg Oncol 28 120 125 10.1053/ejso.2001.1223 1:STN:280:DC%2BD387lt1akuw%3D%3D 11884046 (Pubitemid 35023652)
11. MW Bennett J O'Connell A Houston, et al. 2001 Fas ligand upregulation is an early event in colonic carcinogenesis J Clin Pathol 54 598 604 10.1136/jcp.54.8.598 1:STN:280:DC%2BD3MvivFOitA%3D%3D 11477113 (Pubitemid 32756440)
12. M Shimoyama T Kanda L Liu, et al. 2001 Expression of Fas ligand is an early event in colorectal carcinogenesis J Surg Oncol 76 63 68 10.1002/1096-9098(200101)76:1<63::AID-JSO1011>3.0.CO;2-C 1:STN:280:DC%2BD3M7kvF2rug%3D%3D 11223827 (Pubitemid 32128365)
13. M Younes MR Schwartz D Finnie, et al. 1999 Overexpression of Fas ligand (FasL) during malignant transformation in the large bowel and in Barrett's metaplasia of the esophagus Hum Pathol 30 1309 1313 10.1016/S0046-8177(99)90061- 8 1:CAS:528:DyaK1MXnvVGnur4%3D 10571510 (Pubitemid 29534292)
14. J O'Connell MW Bennett GC O'Sullivan, et al. 1998 Fas ligand expression in primary colon adenocarcinomas: evidence that the Fas counterattack is a prevalent mechanism of immune evasion in human colon cancer J Pathol 186 240 246 10.1002/(SICI)1096-9896(199811)186:3<240::AID-PATH173>3.0.CO;2-L 10211111 (Pubitemid 28494350)
15. JM Michael-Robinson N Pandeya MC Cummings, et al. 2003 Fas ligand and tumour counter-attack in colorectal cancer stratified according to microsatellite instability status J Pathol 201 46 54 10.1002/path.1406 1:CAS:528:DC%2BD3sXotFyqs7Y%3D 12950016 (Pubitemid 37121202)
16. CM van Geelen JL Westra EG de Vries, et al. 2006 Prognostic significance of tumor necrosis factor-related apoptosis-inducing ligand and its receptors in adjuvantly treated stage III colon cancer patients J Clin Oncol 24 4998 5004 10.1200/JCO.2006.06.8809 17075118 (Pubitemid 46631402)
17. JJ Koornstra FE Rijcken S de Jong, et al. 2004 Assessment of apoptosis by M30 immunoreactivity and the correlation with morphological criteria in normal colorectal mucosa, adenomas and carcinomas Histopathology 44 9 17 10.1111/j.1365-2559.2004.01739.x 1:STN:280:DC%2BD2c%2FitFSmsw%3D%3D 14717663 (Pubitemid 38174864)
18. JR Jass LH Sobin H Watanabe 1990 The World Health Organization's histologic classification of gastrointestinal tumors A commentary on the second edition, Cancer 66 2162 2167 1:STN:280:DyaK3M%2FivFSksA%3D%3D
19. C Caulin GS Salvesen RG Oshima 1997 Caspase cleavage of keratin 18 and reorganization of intermediate filaments during epithelial cell apoptosis J Cell Biol 138 1379 1394 10.1083/jcb.138.6.1379 1:CAS:528:DyaK2sXmt1yjsbk%3D 9298992 (Pubitemid 27415063)
20. MP Leers W Kolgen V Bjorklund, et al. 1999 Immunocytochemical detection and mapping of a cytokeratin 18 neo-epitope exposed during early apoptosis J Pathol 187 567 572 10.1002/(SICI)1096-9896(199904)187:5<567::AID- PATH288>3.0.CO;2-J 1:CAS:528:DyaK1MXisFarsL4%3D 10398123 (Pubitemid 29151999)
21. R Dolcetti A Viel C Doglioni, et al. 1999 High prevalence of activated intraepithelial cytotoxic T lymphocytes and increased neoplastic cell apoptosis in colorectal carcinomas with microsatellite instability Am J Pathol 154 1805 1813 1:STN:280:DyaK1M3ptlShtA%3D%3D 10362805
22. TC Smyrk P Watson K Kaul, et al. 2001 Tumor-infiltrating lymphocytes are a marker for microsatellite instability in colorectal carcinoma Cancer 91 2417 2422 10.1002/1097-0142(20010615)91:12<2417::AID-CNCR1276>3.0.CO;2-U 1:STN:280:DC%2BD3MzkvFGqsA%3D%3D 11413533 (Pubitemid 32552830)
23. G Deng I Bell S Crawley, et al. 2004 BRAF mutation is frequently present in sporadic colorectal cancer with methylated hMLH1, but not in hereditary nonpolyposis colorectal cancer Clin Cancer Res 10 191 195 10.1158/1078-0432.CCR- 1118-3 1:CAS:528:DC%2BD2cXkvF2msA%3D%3D 14734469 (Pubitemid 38114179)
24. V Johnson E Volikos SE Halford, et al. 2005 Exon 3 beta-catenin mutations are specifically associated with colorectal carcinomas in hereditary non-polyposis colorectal cancer syndrome Gut 54 264 267 10.1136/gut.2004.048132 1:CAS:528:DC%2BD2MXhsVagt70%3D 15647192 (Pubitemid 40139244)
25. L Losi R Fante C Di Gregorio, et al. 1995 Biologic characterization of hereditary non-polyposis colorectal cancer Nuclear ploidy, AgNOR count, microvessel distribution, oncogene expression, and grade-related parameters. Am J Clin Pathol 103 265 270 1:STN:280:DyaK2M7nslSrtQ%3D%3D
26. OK Yagi Y Akiyama T Nomizu, et al. 1998 Proapoptotic gene BAX is frequently mutated in hereditary nonpolyposis colorectal cancers but not in adenomas Gastroenterology 114 268 274 10.1016/S0016-5085(98)70477-9 1:CAS:528:DyaK1cXpt1Kjtg%3D%3D 9453486 (Pubitemid 28093533)
27. JR Jass 2004 HNPCC and sporadic MSI-H colorectal cancer: a review of the morphological similarities and differences Fam Cancer 3 93 100 10.1023/B:FAME.0000039849.86008.b7 1:CAS:528:DC%2BD2cXntFCntbk%3D 15340259 (Pubitemid 40645890)
28. J Young LA Simms KG Biden, et al. 2001 Features of colorectal cancers with high-level microsatellite instability occurring in familial and sporadic settings: parallel pathways of tumorigenesis Am J Pathol 159 2107 2116 1:CAS:528:DC%2BD38Xhslaqsw%3D%3D 11733361
29. DM Heijink JH Kleibeuker M Jalving, et al. 2007 Independent induction of caspase-8 and cFLIP expression during colorectal carcinogenesis in sporadic and HNPCC adenomas and carcinomas Cell Oncol 29 409 419 1:CAS:528: DC%2BD2sXovFWju7w%3D 17726263
30. Rijcken FE, Koornstra JJ, van der Sluis T et al (2007) Early carcinogenic events in HNPCC adenomas: differences with sporadic adenomas. Dig Dis Sci [Epub ahead of print]
31. FA Sinicrope G Roddey M Lemoine, et al. 1998 Loss of p21WAF1/Cip1 protein expression accompanies progression of sporadic colorectal neoplasms but not hereditary nonpolyposis colorectal cancers Clin Cancer Res 4 1251 1261 1:STN:280:DyaK1c3mvVKjsg%3D%3D 9607584
32. FA Sinicrope M Lemoine L Xi, et al. 1999 Reduced expression of cyclooxygenase 2 proteins in hereditary nonpolyposis colorectal cancers relative to sporadic cancers Gastroenterology 117 350 358 10.1053/gast.1999.0029900350 1:CAS:528:DyaK1MXltFKqtr8%3D 10419916 (Pubitemid 29352943)
33. AM Houston JM Michael-Robinson MD Walsh, et al. 2008 The "Fas counterattack" is not an active mode of tumor immune evasion in colorectal cancer with high-level microsatellite instability Hum Pathol 39 243 250 10.1016/j.humpath.2007.06.010 1:CAS:528:DC%2BD1cXovFOjsw%3D%3D 17961631
34. JM Michael-Robinson A Biemer-Huttmann DM Purdie, et al. 2001 Tumour infiltrating lymphocytes and apoptosis are independent features in colorectal cancer stratified according to microsatellite instability status Gut 48 360 366 10.1136/gut.48.3.360 1:CAS:528:DC%2BD3MXitlCjur8%3D 11171826 (Pubitemid 32269564)
35. PA Jackson MA Green CG Marks, et al. 1996 Lymphocyte subset infiltration patterns and HLA antigen status in colorectal carcinomas and adenomas Gut 38 85 89 10.1136/gut.38.1.85 1:STN:280:DyaK287msFSjsQ%3D%3D 8566865
36. CA Rubio B Jacobsson E Castaños-Velez 1999 Cytotoxic intraepithelial lymphocytes in colorectal polyps and carcinomas Anticancer Res 19 4B 3221 3227 1:STN:280:DC%2BD3c7hvVajug%3D%3D 10652615
37. M Warabi M Kitagawa K Hirokawa 2000 Loss of MHC class II expression is associated with a decrease of tumor-infiltrating T cells and an increase of metastatic potential of colorectal cancer: immunohistological and histopathological analyses as compared with normal colonic mucosa and adenomas Pathol Res Pract 196 807 815 1:CAS:528:DC%2BD3MXps1Whtg%3D%3D 11156321
38. M Guidoboni R Gafà A Viel, et al. 2001 Microsatellite instability and high content of activated cytotoxic lymphocytes identify colon cancer patients with a favorable prognosis Am J Pathol 159 297 304 1:STN:280: DC%2BD3Mzpt1arsQ%3D%3D 11438476
39. Y Naito K Saito K Shiiba, et al. 1998 CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer Cancer Res 58 3491 3494 1:CAS:528:DyaK1cXlsFajsb4%3D 9721846
40. KM Ropponen MJ Eskelinen PK Lipponen, et al. 1997 Prognostic value of tumour-infiltrating lymphocytes (TILs) in colorectal cancer J Pathol 182 318 324 10.1002/(SICI)1096-9896(199707)182:3<318::AID-PATH862>3.0.CO;2-6 1:STN:280:DyaK1c%2FgvF2nug%3D%3D 9349235 (Pubitemid 27285785)
41. J Dhein H Walczak C Baumler, et al. 1995 Autocrine T-cell suicide mediated by APO-1/(Fas/CD95) Nature 373 438 441 10.1038/373438a0 1:CAS:528:DyaK2MXjsFCjsL4%3D 7530335
42. A Houston FD Waldron-Lynch MW Bennett, et al. 2003 Fas ligand expressed in colon cancer is not associated with increased apoptosis of tumor cells in vivo Int J Cancer 107 209 214 10.1002/ijc.11392 1:CAS:528:DC%2BD3sXnsFahtr0%3D 12949796 (Pubitemid 37152899)
43. A Houston MW Bennett GC O'Sullivan, et al. 2003 Fas ligand mediates immune privilege and not inflammation in human colon cancer, irrespective of TGF-beta expression Br J Cancer 89 1345 1351 10.1038/sj.bjc.6601240 1:CAS:528:DC%2BD3sXns1Cmuro%3D 14520470 (Pubitemid 37363427)
44. K Okada K Komuta S Hashimoto, et al. 2000 Frequency of apoptosis of tumor-infiltrating lymphocytes induced by fas counterattack in human colorectal carcinoma and its correlation with prognosis Clin Cancer Res 6 3560 3564 1:CAS:528:DC%2BD3cXntFCisLw%3D 10999744
45. JA Walker P Quirke 2001 Viewing apoptosis through a TUNEL J Pathol 195 275 276 10.1002/path.979 1:STN:280:DC%2BD3MrmslCjsQ%3D%3D 11673822 (Pubitemid 32998351)
46. J O'Connell A Houston MW Bennett GC O'Sullivan F Shanahan 2001 Immune privilege or inflammation? Insights into the Fas ligand enigma Nat Med 7 271 274 10.1038/85395 11231613 (Pubitemid 32224332)
47. NP Restifo 2000 Not so Fas: Re-evaluating the mechanisms of immune privilege and tumor escape Nat Med 6 493 495 10.1038/74955 1:CAS:528: DC%2BD3cXjtFyhsrw%3D 10802692 (Pubitemid 30305889)
48. J Sträter P Möller 2003 CD95 (Fas/APO-1)/CD95L in the gastrointestinal tract: fictions and facts Virchows Arch 442 218 225 12647210
49. V Huber S Fais M Iero, et al. 2005 Human colorectal cancer cells induce T-cell death through release of proapoptotic microvesicles: role in immune escape Gastroenterology 128 1796 1804 10.1053/j.gastro.2005.03.045 1:CAS:528:DC%2BD2MXlvFKls7w%3D 15940614 (Pubitemid 40824690)
50. J O'Connell GC O'Sullivan JK Collins, et al. 1996 The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand J Exp Med 184 1075 1082 10.1084/jem.184.3.1075 9064324
51. AE Ryan F Shanahan J O'Connell, et al. 2005 Addressing the "Fas counterattack" controversy: blocking fas ligand expression suppresses tumor immune evasion of colon cancer in vivo Cancer Res 65 9817 9823 10.1158/0008-5472.CAN-05-1462 1:CAS:528:DC%2BD2MXhtFKktLzJ 16267003 (Pubitemid 41541459)
52. Favre-Felix N, Fromentin A, Hammann A et al (2000) Cutting edge: the tumor counterattack hypothesis revisited: colon cancer cells do not induce T cell apoptosis via the Fas (CD95, APO-1) pathway. J Immunol 5023-5027
53. H Arai D Gordon EG Nabel, et al. 1997 Gene transfer of Fas ligand induces tumor regression in vivo Proc Natl Acad Sci USA 94 13862 13867 10.1073/pnas.94.25.13862 1:CAS:528:DyaK2sXotVart7k%3D 9391118 (Pubitemid 28009675)
54. A Jekle R Obst F Lang, et al. 2000 CD95/CD95 ligand-mediated counterattack does not block T cell cytotoxicity Biochem Biophys Res Commun 272 395 399 10.1006/bbrc.2000.2792 1:CAS:528:DC%2BD3cXjs12gu74%3D 10833425 (Pubitemid 30444629)